ROIVANT SCIENCES LTD. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)
ROIVANT SCIENCES LTD. (ROIV) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) of $0 for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome · last filed 2026-05-20
- ROIVANT SCIENCES LTD. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for the quarter ending 2026-03-31 was $0.00.
- ROIVANT SCIENCES LTD. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ROIVANT SCIENCES LTD. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ROIVANT SCIENCES LTD. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for the quarter ending 2025-06-30 was $0.00.
- ROIVANT SCIENCES LTD. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for fiscal 2026 was $0.00.
- ROIVANT SCIENCES LTD. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for fiscal 2025 was -$1.20M.
- ROIVANT SCIENCES LTD. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for fiscal 2024 was $0.00.
- ROIVANT SCIENCES LTD. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for fiscal 2023 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $0.00 derived: sum of 2 quarters · filed 2026-05-20 | $0.00 derived: sum of 3 quarters · filed 2026-05-20 | $0.00 10-K · filed 2026-05-20 |
| 2025-12-31 | $0.00 10-Q · filed 2026-02-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-06 | $0.00 10-Q · filed 2026-02-06 | $0.00 derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 3 quarters · filed 2026-05-20 | $2.30M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-20 | $2.30M derived: sum of 3 quarters · filed 2026-05-20 | $9.40M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $2.30M derived: sum of 2 quarters · filed 2026-05-20 | $9.40M derived: sum of 3 quarters · filed 2026-05-20 | -$1.20M 10-K · filed 2026-05-20 |
| 2024-12-31 | $2.30M 10-Q · filed 2026-02-06 | $9.40M derived: sum of 2 quarters · filed 2026-02-06 | -$1.20M 10-Q · filed 2026-02-06 | -$1.20M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | $7.10M 10-Q · filed 2025-11-10 | -$3.50M 10-Q · filed 2025-11-10 | -$3.50M derived: sum of 3 quarters · filed 2026-05-20 | -$3.50M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | -$10.60M 10-Q · filed 2025-08-11 | -$10.60M derived: sum of 2 quarters · filed 2026-05-20 | -$10.60M derived: sum of 3 quarters · filed 2026-05-20 | -$10.60M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $0.00 derived: sum of 2 quarters · filed 2026-05-20 | $0.00 derived: sum of 3 quarters · filed 2026-05-20 | $0.00 10-K · filed 2026-05-20 |
| 2023-12-31 | $0.00 10-Q · filed 2025-02-10 | $0.00 derived: sum of 2 quarters · filed 2025-02-10 | $0.00 10-Q · filed 2025-02-10 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $0.00 10-K · filed 2025-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |